Policy
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
FEATURED STORIES
Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are keeping many of the terms of their agreements private.
Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis by the Rare Disease Company Coalition shows. That could mean $4 billion in missed revenue for already cash-strapped biotechs.
The FDA’s rare pediatric disease priority review voucher program missed reauthorization at the last minute in 2024; advocates have been fighting to get it back ever since.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Researchers are calling for a “paradigm shift” in indoor ventilation systems to combat COVID-19 and other airborne pathogens.
Proxalutamide, a selective high-affinity silent antagonist of the androgen receptor, is being developed by Chinese biotech, Kintor Pharmaceutical Limited (9939.HK).
Overall, the researchers claim this “Disinformation Dozen” generate approximately 65% of the anti-vaccine misinformation on these platforms.
Stem cell therapy has been available for decades, but the medical field hasn’t fully used its treatment for all applications. In fact, the U.S. FDA has been warning people about using some stem cell therapies and deemed them illegal while others have strict restrictions on their use.
Pfizer’s clinical trials diversity report showed the disproportionate way the virus impacted minority communities in the U.S., increasing the calls for racial and ethnic diversity in clinical studies.
Shares of Heron Therapeutics climbs after it announced the U.S. FDA approved its non-opioid drug for extended pain relief following some surgeries.
Emergent company executives Fuad El-ibri and Robert Kramer will be testifying before a congressional probe after a botched batch of 15 million doses of J&J’s COVID-19 vaccine.
Comments on social media provide a glimpse at the deep divide in trust of public health agencies, and now a new survey demonstrates the breadth of that distrust.
There was a lot of news and research studies today related to the COVID-19 vaccines. Here’s a look.
In the U.S., many states and organizations are using unique tactics to improve vaccination rates including setting up mobile vans, offering $100 incentives, and free beers.